Menu
Not yet recruiting NCT07060352

Estimating the Prevalence of GAstrocnemius Muscle REtraction in a Population Suffering From Plantar aPOneurositis and Describing the Effects of Lengthening

No phase Interventional Plantar Fasciitis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Ankle Dorsiflexion Index (ADI) measurement.
Who it may be relevant to
Registry conditions: Plantar Fasciitis. Basic parameters: 18 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The gastrocnemius muscles, which form the upper part of the calf, can suffer from retraction, a common but often under-diagnosed condition, which can be a risk factor for plantar fasciitis. Retraction can be treated medically, by stretching, or surgically, by lengthening the muscles. Gastrocnemius retraction is difficult to measure, but tests such as the Ankle Dorsiflexion Index (ADI) provide a more accurate assessment. Knowing the prevalence of this retraction in patients suffering from plantar fasciitis would enable us to improve diagnostic criteria and better target treatments. Surgical lengthening of the gastrocnemius, particularly by tenotomy, is effective in cases of chronic plantar fasciitis, even without apparent muscle retraction.

Interventions

  • Diagnostic test Ankle Dorsiflexion Index (ADI) measurement
    Ankle Dorsiflexion Index (ADI) measurement at D0 and W8

Primary outcome measures

  • Prevalence of gastrocnemius muscle retraction in patients with plantar fasciitis [Time frame: At Day 0]
Secondary outcome measures (12)
  • correlation between ADI measurement and Manchester Oxford Foot Questionnaire (MOXFQ) [Time frame: At Day 0]
  • correlation between ADI measurement and pain Visual Analog Scale (VAS) [Time frame: At Day 0]
  • Evolution of Visual Analog Scale (VAS) [Time frame: between Day 0 and Week 8]
  • Evolution of Visual Analog Scale (VAS) [Time frame: between Day 0 and Week 16]
  • Evolution of Visual Analog Scale (VAS) [Time frame: between Day0 and Week 24]
  • Evolution of Manchester Oxford Foot Questionnaire (MOXFQ) [Time frame: between Day 0 and Week 8]
  • Evolution of Manchester Oxford Foot Questionnaire (MOXFQ) [Time frame: between Day 0 and Week 16]
  • Evolution of Manchester Oxford Foot Questionnaire (MOXFQ) [Time frame: between Day 0 and Week 24]
  • Correlation between surgical success and body mass index (BMI) [Time frame: At Day 0]
  • Correlation between surgical success and age of patient [Time frame: At Day 0]
  • Correlation between surgical success and tobacco consumption [Time frame: At Day 0]
  • Correlation between surgical success and location of fasciitis [Time frame: At Day 0]

Eligibility criteria

Inclusion criteria

  • Patient aged 70 or under
  • Patient suffering from unilateral plantar fasciitis that has progressed for more than 6 months and is recalcitrant to medical treatment
  • Collection of express, oral consent
  • Available for follow-up visits

Exclusion criteria

  • Patients with neuropathic pain
  • History of fracture of the lower limb, surgery on the lower limb, inflammatory rheumatism of the lower limb, injury to the Achilles tendon
  • Patient with another painful orthopedic lesion of the legs/feet
  • Patient with surgically treated plantar fasciitis in the year prior to inclusion
  • Persons unable to give consent
  • Not affiliated to a social security scheme
  • Persons under court protection
  • Participant in another study with an ongoing exclusion period

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07060352 · REGAPOP · 2025-A00798-41

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗